Intrathecal administration of human bone marrow mesenchymal stem cells genetically modified with human proenkephalin...

Area of Science:

• Regenerative Medicine
• Neuroscience
• Pain Research

Background:

• Mesenchymal stem cells (MSCs) are explored for neuropathic pain therapy.
• Enhancing MSC efficacy via gene modification, specifically with the human proenkephalin (hPPE) gene, is investigated.
• The study focuses on engineered human bone marrow stem cells (hBMSCs) carrying the hPPE gene (hPPE-hBMSCs).

Purpose of the Study:

• To investigate the antinociceptive effects of hPPE-hBMSCs.
• To evaluate the efficacy of hPPE-hBMSCs in a rat model of chronic constriction injury (CCI)-induced neuropathic pain.
• To assess the impact of hPPE gene transfer on MSC bioactivity.

Main Methods:

• Primary hBMSCs were cultured and modified with the hPPE gene.
• Intrathecal injection of 6 × 10^6 hPPE-hBMSCs into rats with CCI.
• Measurement of paw mechanical withdrawal threshold and thermal latency before and after surgery.
• In vitro and in vivo analysis of hPPE gene transfer effects on MSC bioactivity.

Main Results:

• Gene transfer did not alter hBMSC surface phenotypes or differentiation.
• The hPPE-hBMSC group exhibited improved pain thresholds (mechanical and thermal) on the ipsilateral side starting day 9 post-CCI.
• The analgesic effect was antagonized by naloxone, confirming opioid receptor involvement.
• Leucine-enkephalin (L-EK) secretion was significantly increased in the hPPE-engineered hBMSC group.

Conclusions:

• Intrathecal administration of hPPE gene-modified BMSCs effectively alleviates CCI-induced neuropathic pain in rats.
• This therapeutic approach holds potential for treating human neuropathic pain.
• hPPE gene modification enhances the analgesic capacity of BMSCs.